Lessons from EU Research Funding (1998-2013)
ResearchPosted on rand.org Dec 15, 2017Published in: EU Law and Publications (September 2017). doi: 10.2777/667857
The European Commission Research and Innovation Directorate has commissioned a study which seeks to evaluate the role and impact of the European Union's Research Framework Programme activities in the field of Poverty-Related and Neglected Diseases (PRNDs). The study focuses on the impact of past EU funding ([Euro]1.445bn) in PRND research supported from European Union Framework Programmes (FP5-7, 1998-2013), as well as the first European and Developing Countries Clinical Trials Partnership (EDCPT) (2003-2013) and relevant research under the Innovative Medicines Initiative (IMI) (2008-2013). The overarching aim of this work is to evaluate the role of research and development (R&D) on PRNDs in contributing to achieving universal health coverage and improving population health in low- and middle-income countries (LIMCs). Through applying a mixed-methods approach, the evaluation examined the EU portfolio of PRND research, outcomes and impacts associated with EU-funded R&D across different stages of the health innovation pathway and the system-level factors affecting the translation of R&D efforts into universal health coverage (UHC). The evaluation makes nine recommendations addressed to the European Commission, research funders and wider stakeholders in the global health community
This publication is part of the RAND external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.
RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.
